GlobeNewswire

Compuware ThruPut Manager Empowers Next-Generation IT Staff to Optimize Mainframe Batch Execution

Dela

New Visually Intuitive Insight into Workload Scheduling Helps Enterprises Ensure Performance of Critical Back-End Systems While Controlling Costs

 
  • Enterprises must ensure that critical mainframe batch workloads 1) are completed on time, 2) stay within cost parameters and 3) don't interfere with real-time processing that supports digital customer engagement.

  • Batch management can be jeopardized as mainframe responsibilities are transferred to a new generation of IT staff with far less platform experience, and as mainframe environments become increasingly complex.
     
  • ThruPut Manager and its new web interface address these core operational issues by providing IT staff with intuitive, actionable insight into how batch jobs are being initiated and executed, as well as their impact on cost. 

DETROIT, April 03, 2018 (GLOBE NEWSWIRE) -- Compuware today released a new ThruPut Manager web interface that provides mainframe staff with visually intuitive insight into how batch jobs are being initiated and executed-as well as the impact of those jobs on mainframe software licensing costs.

By implementing ThruPut Manager, enterprises can better safeguard performance of both batch and non-batch applications, while avoiding the significant adverse economic impact of preventable spikes in utilization as measured by Rolling 4-Hour Averages (R4HA), the metric upon which IBM bases its software licensing fees.

Additionally, with ThruPut Manager, enterprises can successfully transfer batch management responsibilities to a new generation of IT staff with far less hands-on platform experience-without exposing themselves to related risks such as missed batch execution deadlines, missed service level agreements and excess costs.

Safeguarding performance, controlling costs and smooth ownership transfers are more critical than ever given the growing importance of mainframe systems. According to a commissioned study conducted by Forrester Consulting on behalf of Compuware, 57 percent of enterprises with a mainframe run more than half of their business-critical workloads on the platform. And that percentage is expected to increase to 64 percent by 2019. The complete Forrester Opportunity Snapshot report, entitled "Modern Mainframe KPIs Are Key To A Successful Digital Strategy," can be found here.

Batch processing on the mainframe remains critical for many core business functions, such as reconciliation of financial transactions and re-pricing of mutual funds. In many cases, these batch workloads must be completed within a tight time-window. So as the size of a batch workload increases-and as other processing activity consumes an enterprise's finite platform resources-ops staff must take appropriate action. Those actions can include juggling the prioritization of jobs, assigning jobs to alternative LPARs and addressing data dependencies that may be holding up job initiation.

ThruPut Manager empowers IT staff to achieve these operational objectives by:

  • Making it easy to see whether batch jobs are meeting key service metrics-especially how quickly they start executing-and if not, what underlying issues are causing delays or non-initiation.
  • Graphically visualizing how it may be constraining less important workloads to minimize a R4HA peak.
  • Enabling operators to avoid unnecessary R4HA peaks by adaptively shifting workload priorities while still fulfilling business imperatives-rather than limiting them to inflexible "hard-capping."
  • Empowering mainframe ops teams to configure automation rules for initiating batch jobs based on parameters such as business impact, completion windows and workload size.

ThruPut Manager also helps ops teams avoid having too many batch jobs execute at the same time, commonly referred to as "over-initiating," which can cause them to compete for scarce CPU cycles-resulting in extended batch elapsed times and missed schedules, as can happen with IBM's WLM-managed initiators.

"Managing the system utilization and the user's expectations has been a real challenge for us," said Christopher Prenatt, who is the Lead Performance Engineer at Verizon. "The new ThruPut Manager GUI will give us the ability to visualize our batch workload for the first time. We can quickly see how long jobs are sitting in the queue and, if there is a problem, rapidly drill down to what the root cause may be. This will be a great addition for our application teams and ultimately help us get maximum value out of our mainframe."

"As mainframe workloads continue to increase, enterprise IT faces growing challenges in batch execution management," said Rich Ptak of IT analyst firm Ptak Associates. "Compuware ThruPut Manager provides much needed clarity and insight to fine-tune batch execution for optimal value easing budget stresses-even as less-experienced staff take on more mainframe responsibilities."

Compuware today also announced zAdviser, an innovative product that uses machine learning to continuously measure and improve an organization's mainframe DevOps processes and development outcomes. zAdviser measures application quality, development velocity, and the efficiency of a development team-empowering enterprise IT leaders to make evidence-based decisions in support of their continuous improvement efforts.

Today's announcements mark the 14th consecutive quarter that Compuware has announced significant innovation in the modernization and mainstreaming of the mainframe. This innovation is of vital importance to large enterprises that must get maximum business value from their mainframe environments-which are doing double-duty as both self-contained core systems of record, and as powerful back-end data and transaction processing systems for front-end customer-facing web and mobile applications.

"Enterprise CIOs have come to realize that high-cost, high-risk attempts to re-platform their supremely valuable mainframe applications make no sense. The less costly, less risky and higher return strategy is to simply adopt better technology for modernizing on platform and mainstreaming mainframe development, operations and security," said Chris O'Malley, CEO of Compuware. "Compuware is redefining what mainframe modernization means and is committed to delivering what customers need to enable them to adopt the smarter strategy."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum